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 2 
SUMMARY 18 
 19 
NFAT1 is a transcription factor that elicits breast carcinoma cells to become invasive, 20 
contributing thus to formation of metastasis. The molecular mechanisms by which 21 
NFAT1 operates in this respect are still poorly known. Here, we report that NFAT1 22 
increases Lipocalin 2 (LCN2) mRNA and protein expression by binding to specific sites 23 
in the LCN2 gene promoter region. We show that the LCN2 protein is required 24 
downstream of NFAT1 to increase breast cancer cell invasion. We demonstrate that the 25 
NFAT1/LCN2 axis is sufficient to regulate expression of the TNF-like receptor 26 
TWEAKR at the RNA level and of its ligand, TWEAK, at the protein level. We show, 27 
however, that TWEAKR mediates an anti-invasive effect in breast cancer cells whereas, 28 
depending on LCN2 expression, TWEAK has either anti- and pro-invasive capacities. 29 
Thus, we identify LCN2 and TWEAKR/TWEAK as critical downstream effectors of 30 
NFAT1 to regulate breast cancer cell motility and invasive capacity. 31 
 32 
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Introduction  34 
Metastases are the main cause of morbidity and mortality in breast cancer patients. 35 
Their efficient dissemination is directly linked to the invasive behaviour of cancer cells 36 
(Friedl and Wolf 2003), which requires the cells to destroy and reorganize the extra-cellular 37 
matrix as well as the capacity to migrate. This is a complex process involving many players 38 
among which NFAT transcription factors, especially NFAT1, are critical (Jauliac et al. 2002; 39 
Yoeli-Lerner et al. 2005).  40 
The family of NFAT transcription factors comprises five genes (NFAT1 to 5). NFAT1, 41 
NFAT2, NFAT3 and NFAT4 were first identified as T cell transcription factors that bind IL-2 42 
promoter after cell activation (Shaw et al. 1988), while NFAT5 is induced by osmotic stress 43 
(Lopez-Rodriguez et al. 1999). Because of their role in critical signalling pathways that 44 
control cell fate (Baksh et al. 2002; Chuvpilo et al. 2002; Xanthoudakis et al. 1996), one 45 
would expect that disturbing NFAT signalling could impact carcinogenesis. Indeed, beside 46 
their role in the migratory and invasive capacities of breast cancer cells (Fougère et al. 2010; 47 
Jauliac et al. 2002; Yiu and Toker 2006; Yoeli-Lerner et al. 2005, Germann et al; 2012), there 48 
is growing evidence for an active role of NFAT factors in carcinogenesis (Buchholz et al. 49 
2006; Dejmek et al. 2006; Foldynová-Trantírková et al. 2010; Holzmann et al. 2004; Jönsson 50 
et al. 2002). However, beside these reports of a “pro-cancer” role, others are showing the 51 
“anti-cancer” capacities of NFAT factors (Glud et al. 2005; Lee et al. 2005; Wu et al. 2010). 52 
In line with this duality of function, we have reported that NFAT3 is specifically expressed in 53 
oestrogen receptor +-positive breast cancer cells and, contrary to NFAT1 and NFAT5, 54 
inhibits these cells' motility by blocking LCN2 (Lipocalin 2) gene expression (Fougère et al. 55 
2010). 56 
LCN2 is a secreted protein of the Lipocalin family (Flower 1996), the high expression 57 
of which is associated with malignancy in different types of cancers (Bartsch and Tschesche 58 
1995; Furutani et al. 1998; Missiaglia et al. 2004; Nielsen et al. 1996), including breast cancer 59 
(Stoesz et al. 1998), and is a predictor of breast cancer progression (Hu et al. 2008).  Actually, 60 
LCN2 regulates cell migration (Fougère et al. 2010; Leng et al. 2008; Playford et al. 2006) 61 
and formation of metastases (Shi et al. 2008; Yang et al. 2009). LCN2 is induced under 62 
diverse inflammatory conditions (Nielsen et al. 1996), and it is known that inflammation is 63 
strongly linked to tumorigenesis (Balkwill and Mantovani 2001; Iliopoulos, Hirsch, and 64 
Struhl 2009; Pierce et al. 2009) and metastasis formation.  65 
Apart from LCN2, other inflammatory molecules, such as those of the 66 
TWEAK/TWEAKR cytokine receptor axis, have been linked to cancer. TWEAK (TNF-67 
related Weak Inducer of Apoptosis) belongs to the TNF family and is involved in many 68 
diseases (Winkles 2008) including breast cancer (Willis et al. 2008). TWEAKR (TNF-related 69 
Weak Inducer of Apoptosis Receptor, Fn14) expression has been observed in breast tumour 70 
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 4 
samples, where it might regulate cancer cell migration (Michaelson et al. 2005; Willis et al. 71 
2008). Indeed, the positive role of the TWEAK/TWEAKR axis on cancer cell migration has 72 
been reported (Dai et al. 2009; Tran et al. 2006), but there are also reports that TWEAK 73 
inhibits migration (Meighan-Mantha et al. 1999). Recently, a preclinical study has shown that 74 
a humanized antibody directed against the TWEAKR can mediate anti-tumour effects by 75 
signalling through TWEAKR (Culp et al. 2010).  76 
Here, we report that signalling through NFAT1 up-regulates LCN2 expression by 77 
NFAT1 direct binding on LCN2 promoter and that LCN2 is required for NFAT1 to foster 78 
breast cancer cell invasion. Downstream of NFAT1 and LCN2, we identify the 79 
TWEAKR/TWEAK axis as a key player for regulating the invasive process, and show that, 80 
depending on LCN2 expression level, TWEAK displays both anti-invasive and pro-invasive 81 
functions. Thus, we uncover a novel NFAT1/LCN2/TWEAKR/TWEAK axis critical to 82 
regulate breast cancer cell invasion.  83 
84 
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Results 85 
 86 
NFAT1 up-regulates LCN2 expression in breast cancer cells 87 
Having recently shown that NFAT3 inhibits LCN2 transcription in breast cancer cells 88 
(Fougère et al., 2010), we evaluated here the effect of NFAT1 on LCN2 expression. However, 89 
since NFAT1 and LCN2 proteins are essentially not expressed in oestrogen receptor-positive 90 
(ERA
+
) cancer cells (Fougère et al., 2010), this was done only using ERA-negative (ERA
-
) 91 
cells in which, contrary to NFAT3, NFAT1 and LCN2 are highly expressed.  First, we used 92 
NFAT1-specific siRNA to silence endogenous NFAT1 in MDA-MB-231, which reduced its 93 
expression by 90% (Fig. 1A, right panel) without affecting that of NFAT5 or NFAT4 (data 94 
not shown). NFAT1 silencing (which did not result in cell apoptosis as assayed by annexin V 95 
labelling data; not shown) reduced by 5-fold LCN2 mRNA expression relative to control cells 96 
(Fig. 1A, left panel), and abrogated both intracellular (Fig. 1B, left panel) and secreted (Fig. 97 
1B, middle panel) LCN2 protein expression.  98 
We next examined whether transiently transfected ectopic NFAT1 affected LCN2 99 
protein expression. Because only 10% of cell were actually transfected, empty vector control 100 
(Fig. 1B, right panel, vector) and NFAT1 (Fig. 1B, right panel, NFAT1) were cotransfected 101 
with a GFP-expressing vector in order to identify transfected cells. Thus, NFAT1 over-102 
expression increased LCN2 protein expression relative to control cells as assessed by Western 103 
blot analysis (Fig. 1B, right panel). 104 
Thus, in contrast to NFAT3 (Fougère et al. 2010), NFAT1 up-regulates both LCN2 105 
mRNA and protein expression in breast cancer cells. 106 
 107 
Downstream of NFAT1, LCN2 is key to increase breast cancer cell invasion  108 
LCN2 plays a critical role in regulating breast cancer cell motility (Fougère et al. 109 
2010). In order to evaluate the physiological relevance of LCN2 modulation by NFAT1, we 110 
tested whether LCN2 was involved in NFAT1-regulated chemoinvasion. Transiently 111 
transfecting MDA-MB-231 cells with HA epitope-tagged LCN2 (Fig. 1C, left panel) 112 
increased breast cancer cell chemoinvasion as compared with empty vector-transfected cells 113 
(Fig. 1C, right panel), indicating LCN2 role in the process. To evaluate whether LCN2 114 
expression downstream of NFAT1 was needed to regulate chemoinvasion, we transiently co-115 
transfected the cells with T7 epitope-tagged NFAT1 together with either control or LCN2-116 
targeted siRNA (Fig. 1D, right panel)and  in combination with a betagalactosidase (!-gal) 117 
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 6 
expressing vector. NFAT1 increased chemoinvasion in the presence of LCN2, whereas 118 
silencing LCN2 precluded NFAT1 pro-invasive effect (si LCN2 / NFAT1), as compared with 119 
cells transfected with both control and NFAT1 siRNAs (si ctrl / NFAT1), and was inhibitory 120 
by itself (si LCN2) (Fig. 1D, left panel). These results indicate that LCN2 expression 121 
downstream of NFAT1 is required to regulate breast cancer cell invasion.  122 
 123 
NFAT1 binds to the LCN2 promoter region to up-regulate LCN2 expression 124 
 To more thoroughly analyse the relationship between LCN2 expression and NFAT1 125 
signalling, we investigated the LCN2 promoter region where 6 potential NFAT-binding sites 126 
(-881, -522, -501, -441, -409, -142) (Fig. 2A) have been identified (Fougère et al. 2010). 127 
Using a Luciferase gene-fused LCN2 promoter, we found that NFAT1 ectopic expression 128 
doubled the promoter activity relative to empty vector-transfected cells (Fig. 2B). To assess 129 
whether endogenous NFAT1 interacted with LCN2 promoter region, chromatin 130 
immunoprecipitation (ChIP) was performed in cells treated by control or NFAT1-specific 131 
siRNAs: indeed, endogenous NFAT1 bound to LCN2 promoter whereas no significant signal 132 
enrichment was noted when NFAT1 was silenced (Fig. 2C, si ctrl versus si NFAT1).  To 133 
confirm NFAT1 binding to LCN2 promoter region and determine whether NFAT1 putative 134 
binding sites are functional in vivo, we individually mutated each of these. Measurement of 135 
Luciferase activity after transient co-transfection of MDA-MB-231 cells with NFAT1 of 136 
mutated LCN2 promoter revealed that the -409 binding site was required for NFAT1 to 137 
increase transcriptional activity, the -501 and-142 sites being required for LCN2 promoter 138 
basal activity (Fig. 2D). Electrophoretic mobility shift assays were then performed to confirm 139 
that endogenous NFAT1 bound to these identified sites and, indeed, NFAT1 bound to the -140 
501, -409, -142 wild-type, but not mutated, binding sites (Fig. 2E). NFAT1-specific binding 141 
was confirmed by pre-incubating nuclear extracts with an anti-NFAT1 antibody that 142 
supershifts the complex NFAT1/probe (Fig. 2E, arrows). As control, no supershift was 143 
induced by pre-incubating nuclear extracts with control IgG. 144 
 These data demonstrate that endogenous NFAT1 binds directly to the LCN2 promoter 145 
-501, -142 sites to modulate its basal expression, and to the -409 site to regulate its inducible 146 
expression. 147 
 148 
The NFAT1/LCN2 axis modulates TWEAKR expression 149 
To assess the mechanisms by which the NFAT1/LCN2 axis up-regulates breast cancer 150 
cell invasion, we used transcriptome analysis of LCN2-specific siRNA-treated MDA-MB-231 151 
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 7 
cells in order to identify genes regulated by LCN2 potentially involved in the invasive 152 
capacity. LCN2 silencing impacted 95 genes by at least 1.5 fold (95% confidence level) (Fig. 153 
3A, and Supplementary Table 1), which was confirmed by RT-QPCR for most of these (data 154 
not shown). Because we have shown that NFAT1 regulates LCN2 expression, we examined 155 
whether modifying NFAT1 expression affected any of the 95 LCN2-regulated genes. Indeed, 156 
siRNA silencing of NFAT1 reduced expression of two of them: TWEAKR (TNFSFR12A) 157 
(Fig. 3B) and C6ORF55 (VTA1) (data not shown). Thus, out of the 95 identified genes that 158 
putatively could be involved in the invasion process of breast cancer cells, only these two 159 
were regulated in the same manner by NFAT1 and LCN2. Silencing VTA1 with siRNA had 160 
no effect on cancer cell invasive capacity (data not shown). Because TWEAKR was already 161 
known to participate in the motility of different cell types (Meighan-Mantha et al. 1999; 162 
Willis et al. 2008) and was regulated in the same manner by NFAT1 and LCN2, we further 163 
investigated this regulation of TWEAKR expression by LCN2 and NFAT1 and its role in the 164 
invasive behaviour of breast cancer cells. Flow cytometry analysis confirmed that siRNA 165 
silencing of either LCN2 or NFAT1 down-regulated TWEAKR protein expression in MDA-166 
MB-231 (Fig. 3C) and SUM-159-PT (Supplementary Fig. S1) cells relative to control cells. 167 
These data indicate that TWEAKR is regulated by NFAT1 and LCN2 at the mRNA 168 
and protein levels in breast cancer cells. 169 
 170 
Reciprocal regulation of the TWEAKR/TWEAK axis and LCN2 expression 171 
In contrast to TWEAKR, silencing or overexpressing LCN2 in MDA-MB-231 cells 172 
did not modify mRNA levels of its ligand, TWEAK (Supplementary Fig. S2A and B), which 173 
was indeed not found among the 95 genes identified in Fig. 3A (see Supplementary Table 1). 174 
Nonetheless, when LCN2 or NFAT1 were independently silenced with siRNA directed to 175 
either, which reduced their expression by 90%, TWEAK protein levels in cell supernatants 176 
increased relative to the control condition (Fig. 4A). To validate that TWEAK protein is 177 
regulated by LCN2, cells were transiently transfected with a fixed amount of a TWEAK-178 
expressing vector and increasing amounts of a LCN2-expressing vector, which resulted in 179 
dose-dependent decrease of TWEAK levels (Fig. 4B). Moreover, TWEAKR depletion by 180 
siRNA led to increased TWEAK protein levels without modifying its mRNA expression in 181 
MDA-MB-231 and SUM-159-PT cells (Supplementary Fig. S3).   182 
Because LCN2 regulated TWEAK protein amount, we verified whether TWEAK or 183 
TWEAKR per se affected LCN2 protein levels by transiently transfecting MDA-MB-231 184 
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 8 
cells with siRNA targeting TWEAKR or TWEAK. Indeed, silencing of either led to LCN2 185 
level increase and this effect was cumulative (Fig. 4C). Moreover, TWEAK and TWEAKR 186 
depletion up-regulated LCN2 mRNA expression (Fig. 4D), suggesting a transcriptional link. 187 
To confirm this link, the cells were pre-treated by a transcriptional inhibitor (actinomycin D), 188 
which inhibited LCN2 mRNA increase elicited by TWEAK and TWEAKR depletion. We 189 
verified here that silencing TWEAKR and/or TWEAK did not modify cell apoptosis or 190 
proliferation (Supplementary Fig. S4A). No effect of TWEAK and TWEAKR depletion on 191 
NFAT1 transcriptional activity was noted, suggesting that other unidentified transcription 192 
factors are involved in up-regulating LCN2 expression (data not shown).  193 
Altogether, these results point to a novel axis by which LCN2 modulates TWEAKR at 194 
the mRNA level and its cognate ligand TWEAK at the protein level, both of which 195 
conversely regulate LCN2 expression at the transcriptional level.  196 
 197 
TWEAK increases breast cancer cell invasion independently of the TWEAKR 198 
TWEAKR signalling has already been implicated in the invasive process in different 199 
cell models. To validate that TWEAKR was involved in the chemotactic invasive capacity of 200 
MDA-MB-231 cells, chemoinvasion assays were performed in the presence or not of 201 
recombinant TWEAK, whose presence was thus shown to increase invasion (Fig. 5A). 202 
However, blocking TWEAKR with a specific neutralizing antibody also increased invasion as 203 
compared to control IgG, and adding recombinant TWEAK potentiated this effect (Fig. 5A), 204 
neither of which modifying cell apoptosis or proliferation (Supplementary Fig. S4B, C). 205 
When we repeated the experiment in NFAT1-transfected cells, again pre-treatment with the 206 
TWEAKR neutralising antibody enhanced chemoinvasion elicited by NFAT1 (Fig. 5B), 207 
suggesting that TWEAKR mediates an anti-invasive effect in breast cancer cells in this assay. 208 
As a confirmation, we repeated the experiment presented in Fig. 5A by using a siRNA 209 
targeting TWEAKR. After verifying that the siRNA actually reduced TWEAKR expression 210 
(Fig. 5C, right panel) and did not affect apoptosis or proliferation (Supplementary Fig. S4A), 211 
we found again that chemoinvasion increased when TWEAKR was silenced and that this was 212 
potentiated by adding recombinant TWEAK (Fig. 5C, left panel). 213 
 These findings were surprising in light of the report that, in breast cancer cells, 214 
TWEAKR silencing led to loss of invasion potential (Willis et al. 2008).  But in that case the 215 
assay (Hauck et al. 2002; Hsia et al. 2003) assessed random cell invasion, no chemotactic 216 
gradient  being used, whereas ours is chemoinvasion assay using conditioned medium from 217 
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 9 
NIH3T3 cells in order to create a chemotactic gradient (Albini and Benelli 2007). Therefore, 218 
we examined if the different assays accounted for the discrepancy. To this end MDA-MB-231 219 
cells, transiently transfected with either control or TWEAKR-specific siRNAs, were 220 
comparatively assessed in both assays. Data from Fig. S5 indicate that cells were actually less 221 
invasive and that TWEAKR silencing inhibited invasion in the radom invasion assay, whereas 222 
increased invasion in presence was noted as expected in the chemoinvasion assay. Thus, 223 
TWEAKR would differently influence random and directed cell invasion.  224 
To evaluate the role of LCN2 in regulating invasion downstream of TWEAK, MDA- 225 
MB-231 cells were transiently transfected with control or LCN2-specific siRNAs and 226 
exposed to recombinant TWEAK. In this case, when LCN2 was silenced, TWEAK no longer 227 
increased chemoinvasion (Fig. 5D).  228 
These data identify TWEAKR as a receptor that antagonizes the chemotactic 229 
invasion process of breast cancer cells. Importantly, they indicate that LCN2 is required for 230 
TWEAK to increase chemotactic invasion, either directly or via another as yet unidentified 231 
receptor different from TWEAKR.  232 
 233 
Depending on LCN2 expression TWEAK displays either anti- and pro-invasive activities 234 
in breast cancer cells  235 
Inasmuch as TWEAK availability appeared to be regulated by TWEAKR, LCN2 and 236 
NFAT1, we more precisely examined the role of TWEAK protein on breast cancer cell 237 
invasion. MDA-MB-231 cells were transiently transfected with control siRNA or with 238 
siRNAs targeting TWEAKR, LCN2, NFAT1 or TWEAK, alone or in combination (Fig. 6A). 239 
As shown in Fig. 5C, TWEAKR silencing led to increased chemoinvasion, and either NFAT1 240 
(Fig. 6A, si TWR si NFAT1) or LCN2 (Fig. 6A, si TWR si LCN2) depletion prevented this 241 
increase, demonstrating that LCN2 increased expression elicited by TWEAKR knockdown 242 
was responsible for this effect. Indeed, when NFAT1 was silenced, and by consequence 243 
LCN2 too, again the increase of chemoinvasion induced by TWEAKR down-regulation was 244 
abrogated (Fig. 6A, si TWR si NFAT1). Since we have shown that TWEAKR depletion 245 
induces TWEAK protein up-regulation (Supplementary Fig. S3), we examined whether the 246 
latter was involved in this increased invasion. Indeed, when TWEAK was silenced by siRNA 247 
together with TWEAKR (Fig. 6A,  si TWR si TW, -), increased invasion was abolished but it 248 
was rescued by adding back recombinant TWEAK (Fig. 6A, si TWR si TW, +). The same 249 
results were obtained with SUM-159-PT cells (Supplementary Fig. S6). 250 
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These data indicate that TWEAK protein up-regulation is critical to increase invasion 251 
and entails the presence of LCN2.  252 
Interestingly, we have shown that, like TWEAKR down-regulation, that of either 253 
LCN2 or NFAT1 induced increased TWEAK protein levels, albeit without increasing but 254 
rather inhibiting chemoinvasion. Therefore, we hypothesized that, beside its pro-invasive role, 255 
TWEAK might be anti-invasive in the absence of LCN2 or NFAT1. To clarify this 256 
possibility, either LCN2 or NFAT1, alone or in combination with TWEAK, were silenced in 257 
MDA-MB-231 cells. Depletion of endogenous LCN2 inhibited invasion (Fig. 6B, si LCN2) 258 
and up-regulated TWEAK protein (from 27.4 to 73.3 ng/L; Fig. 6B lower panel). TWEAK 259 
up-regulation was critical to blunt invasion when LCN2 was silenced since co-silencing 260 
TWEAK with LCN2 abolished the inhibition of invasion induced by LCN2 knockdown (Fig. 261 
6B, si LCN2 si TW, -), which could be rescued by adding recombinant TWEAK (Fig. 6B, si 262 
LCN2 si TW, +). These results demonstrate that TWEAK, beside its pro-invasive role in the 263 
presence of LCN2, possesses an anti-invasive function in the absence of LCN2. We repeated 264 
the same experiment by depleting NFAT1 and obtained almost the same results as with LCN2 265 
depletion (Fig. 6C), the sole difference being the lack of reversion of the inhibition of 266 
invasion by depleting TWEAK and NFAT1 together (Fig. 6B, si NFAT1 si TW, -). This last 267 
result is not surprising since NFAT1 might certainly target other genes with LCN2 and 268 
TWEAK to regulate breast cancer cell chemoinvasion. Comparable data were obtained using 269 
SUM-159-PT cells (Supplementary Fig. S6). 270 
  Altogether, these data demonstrate that, beside its pro-invasive action, TWEAK has an 271 
anti-invasive action in breast cancer cells in the absence of LCN2. Thus, TWEAK is a pro-272 
invasive factor in breast cancer cells in presence of LCN2 and anti-invasive in its absence.  273 
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Discussion 275 
The role of NFAT transcription factors in breast cancer cell motility has been 276 
identified recently (Jauliac et al. 2002; Mancini and Toker 2009; Yoeli-Lerner et al. 2005) but 277 
it is still poorly understood. Apart from studies indicating that either COX2 (Yiu and Toker 278 
2006) or the autotaxin gene (Chen and O'Connor 2005) are targeted by NFAT1 to increase 279 
invasion and migration, we do not know which other specific signalling pathways these 280 
factors use to modulate breast cancer cell motility. 281 
Recently, a new layer of complexity has been added by the observation that among the 282 
members of the NFAT family, NFAT3 –expressed in less aggressive oestrogen receptor +-283 
positive breast cancer cells– has anti-migratory and anti-invasive actions in contrast to 284 
NFAT1 and NFAT5. One mechanism by which NFAT3 blunts migration is by inhibiting 285 
LCN2 gene expression (Fougère et al. 2010). 286 
Here, we show that LCN2 expression is required for NFAT1 to increase the invasive 287 
capacity of breast cancer cells. We demonstrate that, contrary to NFAT3, NFAT1 binds to 288 
LCN2 promoter to up-regulate LCN2 mRNA and, therefore, protein expression. Together 289 
with our recent report (Fougère et al. 2010), this highlights the differing effects of NFAT 290 
isotypes, despite their high sequence homology, which has already been indicated in specific 291 
knockout murine models (Graef et al. 2001; Ranger et al. 1998; Xanthoudakis et al. 1996) or 292 
by studies on tumour cell transformation (Buchholz et al. 2006; Neal and Clipstone 2003; 293 
Robbs et al. 2008; Wu et al. 2010). These observations suggest that each NFAT isotype 294 
regulates independent set of genes as well as, as demonstrated here for LCN2, differentially 295 
modulates overlapping gene subsets critical for cell fate, and they underscore the idea that 296 
depending on the cell type where they are expressed NFAT isotypes either suppress or 297 
promote oncogenic transformation.  298 
We also evaluated the mechanisms by which LCN2 modulates breast cancer cell 299 
invasion downstream of NFAT1. To this end, we examined the genomic effects of LCN2 300 
depletion in order to identify the genes that are similarly regulated by NFAT1 and LCN2. We 301 
found that, among 95 genes affected by LCN2 down-regulation, two –TWEAKR 302 
(TNFSFR12A) and C6ORF55 (VTA1)– were regulated in the same manner by NFAT1. We 303 
focused on TWEAKR because this gene has already been implicated in the motility of 304 
different cell types (Dai et al. 2009; Tran et al. 2006; Wiley et al. 2001), and silencing VTA1 305 
had no effect in this respect. We found that, at both the mRNA and protein levels, either 306 
NFAT1 or LCN2 down-regulation inhibited TWEAKR expression. We therefore reasoned 307 
that TWEAKR disappearance was responsible for the inhibition of breast cancer cell invasion 308 
J
o
u
rn
a
l 
o
f 
C
e
ll 
S
c
ie
n
c
e
A
c
c
e
p
te
d
 m
a
n
u
s
c
ri
p
t
 12 
in light of reports showing its role in migration and invasion (Dai et al. 2009; Michaelson et 309 
al. 2005; Tran et al. 2006; Willis et al. 2008). Indeed, treating the cells with recombinant 310 
TWEAK elicited increase of their chemoinvasive capacity. Surprisingly, when we silenced 311 
TWEAKR, invasion was increased and TWEAK could still potentiate this increase. We 312 
showed that, in contrast to chemoinvasion, TWEAKR down-regulation inhibited random 313 
invasion as reported (Willis et al., 2008). Therefore, we concluded that, in our chemoinvasion 314 
model, TWEAKR was a receptor that mediated an anti-invasive effect and that its cognate 315 
ligand, TWEAK, could promote invasion via another, as yet unidentified, receptor the 316 
presence of which has already been suggested in RAW264.7 cells (Polek et al. 2003). Hence, 317 
we hypothesised that TWEAK binding to its cognate receptor (TWEAKR) can inhibit 318 
invasion and that blocking this association with a TWEAKR-specific neutralising antibody 319 
enables TWEAK binding to the other receptor that promotes invasion, but it cannot be ruled 320 
out that TWEAK directly enters the cells. Further studies are needed to identify this potential 321 
second TWEAK receptor if it exists. We cannot rule out that NFAT1 and LCN2 participate in 322 
the regulation of this potential unknown TWEAK receptor. 323 
When we examined TWEAK expression in the absence of either LCN2 or NFAT1, we 324 
found that it was up-regulated at the protein, but not the mRNA, level. This demonstrates that 325 
NFAT1, via LCN2, regulates TWEAK protein expression or stability. In the same manner as 326 
for LCN2, inhibiting or silencing TWEAKR elicited up-regulated TWEAK protein expression 327 
or availability. This highlights the tight regulation between LCN2 and the 328 
TWEAKR/TWEAK axis, all the more so that we found also that TWEAKR and TWEAK can 329 
both modulate LCN2 expression at the mRNA and protein levels. Therefore, in breast cancer 330 
cells, there exists a subtle equilibrium between LCN2, TWEAKR and TWEAK to modulate 331 
the availability of these key factors for the regulation of cell invasion (Fig. 7A).  332 
Since we showed that adding recombinant TWEAK increased the cells' invasive 333 
capacity, it was puzzling that elevated TWEAK levels induced by depleting either LCN2 or 334 
NFAT1 correlated with a decrease rather than an increase of invasion. Indeed, our study 335 
shows that presence of LCN2 is necessary for TWEAK to promote its pro-invasive effect 336 
(Fig. 5D).  Therefore, in the absence of LCN2, TWEAK can only signal by the TWEAKR, 337 
and inhibits invasion (Fig. 7B, Without LCN2). Indeed, when TWEAKR is silenced, TWEAK 338 
expression is required to increase invasion and needs the presence of LCN2 (Fig. 6A and 7B, 339 
without TWEAKR). In contrast, in the absence of LCN2, when LCN2 is silenced, TWEAK is 340 
an anti-invasive factor (Fig. 6B). Importantly, this indicates that TWEAK can be either pro-341 
tumorigenic or anti-tumorigenic as reported (Kaduka et al. 2005; Maecker et al. 2005; 342 
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Meighan-Mantha et al. 1999), but in our study these opposite effects occur in the same cells, 343 
suggesting an equilibrium between the two functions (Fig. 7B, Equilibrium). Critically, we 344 
show that LCN2 expression up-regulation by NFAT1 is necessary for TWEAK to increase 345 
breast cancer cell invasion. Therefore, disturbing this tight equilibrium may be a new entry to 346 
inhibit breast cancer cell invasion and ultimately metastasis formation.   347 
Both LCN2 and TWEAK are able to activate the ERK pathway (Gwira et al. 2005; 348 
Peternel et al. 2011; Vincent et al. 2009), ERK apparently being an important actor of breast 349 
cancer cell migration (Irie et al. 2005; Krueger et al. 2001). One possibility would be that 350 
promoting invasion downstream of TWEAK requires modulation of the ERK pathway in 351 
association with LCN2, but this has yet to be determined. 352 
In summary, we have shown that signalling through NFAT1 increases invasion 353 
through a previously unknown LCN2/TWEAKR/TWEAK axis. We demonstrate that 354 
TWEAK can have opposite effects on breast cancer cell invasion: anti-invasive via 355 
TWEAKR, independently of LCN2 (Fig.7B, Without LCN2); pro-invasive via another 356 
unidentified receptor (XR) or directly in association with LCN2 (Fig. 7B, Without TWEAKR). 357 
Therefore, increased NF A T1 activation leads to up-regulation of LCN2 protein expression 358 
that consequently enables TWEAK pro-invasive activity in breast cancer cells.  These 359 
findings underscore the importance of dissecting the mechanisms by which TWEAK and 360 
LCN2 regulate breast cancer cell invasion, downstream of NFAT1, in order to be able to 361 
attempt to therapeutically target this pathway to limit the dissemination of metastasis. 362 
 363 
364 
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Materials and Methods 365 
 366 
Cell culture 367 
The MDA-MB-231 cell line was from the American Type Culture Collection, The 368 
SUM-159-PT cell line was provided by Alex Toker (Harvard Medical School). MDA-MB-369 
231 and SUM-159-PT cells were maintained in Dulbecco Modified Eagle Medium (DMEM), 370 
low glucose (1 g/L D-glucose), 10% Foetal Calf Serum. NIH-3T3 cells were maintained in 371 
DMEM, high glucose (4.5 g/L D-glucose), 10% Newborn Calf Serum. All media were 372 
supplemented with 2 mM L-Glutamine, 100 U/mL Penicillin and 100 _g/mL Streptomycin. 373 
 374 
Antibodies and reagents 375 
The following antibodies were used: Anti-T7 (Novagen; #69522), anti-FLAG (Sigma; 376 
#F1804), anti-HA (Roche; #11867423), anti-NFAT1 from ABR Affinity BioReagent (MAl-377 
025) or from Abcam for ChIP assays (ab2722), anti-Actin (Santa-Cruz Biotechnology; SC-378 
1616), anti-LCN2 (Sigma-Aldrich; HPA002695), and anti-TWEAKR (Abcam; ab21359) for 379 
flow cytometry. The mouse IgG was from Santa-Cruz Biotechnology (SC-2025) and the anti-380 
mouse phycoerythrin-labelled antibody (F0102B) was from R&D systems. The blocking anti-381 
TWEAKR antibody was from R&D systems (#AF1199).  382 
The protein G Plus/Protein A Agarose suspension was from Calbiochem (IP05). 383 
Recombinant human TWEAK (#1090TW/CF) was from R&D Systems. The ELISA used to 384 
assess TWEAK (#DY1090) and LCN2 (#DLCN20) were from R&D systems. SiRNA were 385 
from Dharmacon and their sequences are reported in Supplemental Table 2. Cells were 386 
transiently transfected with the appropriate plasmids using Lipofectamine 2000 (Invitrogen) 387 
or DharmaFECT (Dharmacon) for siRNA according to the manufacturer’s instructions. 388 
 389 
Plasmids, siRNA and quantitative real time reverse transcriptase PCR (RT-QPCR) 390 
NFAT1 was cloned by PCR in the pcDNA3 vector expressing a N-terminal T7-tag. 391 
LCN2 promoter and the pCS4-(n)-,-galactosidase were previously described (Fougère et al. 392 
2010). The potential NFAT-binding sites of LCN2 promoter were mutated by PCR using the 393 
primers described in Supplementaray Table 2. LCN2 was cloned by PCR in the pcDNA3.1+ 394 
vector with a HA tag from RNA isolated from MDA-MB-231 cells. The FLAG-TWEAK 395 
expression vector was from Origene. All constructions were verified by sequencing. To 396 
transiently silence TWEAKR, TWEAK, NFAT1 or LCN2, we used specific siRNAs 397 
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(Dharmacon) at 30 nM, and transfected cells with DharmaFECT for 48 hr. Sequences of the 398 
different siRNAs used are accessible in the Supplementary Table 2. 399 
LCN2, TWEAKR and TWEAK mRNA expression was determined by RT-QPCR. 400 
Total RNA was extracted using the RNeasy mini kit (QIAGEN) according to the 401 
manufacturer’s instructions, and cDNA synthesis was prepared using the SuperScript Reverse 402 
Transcriptase (RT) (Invitrogen). RT-QPCR was performed using SYBR Green PCR Master 403 
Mix on Roche LightCycler as directed by the manufacturer. Cycling parameters were 10 404 
minutes at 95°C followed by 45 cycles of 10 seconds at 95°C (denaturation) and 4 seconds at 405 
68°C (annealing/extension). Primers are accessible in the Supplementary Information, 406 
Supplementary Table 2. 407 
 408 
Proteins detection 409 
For all assays using transfected cells, expression or silencing of the protein were 410 
verified by immunoblotting. Harvested cells were washed twice and resuspended in cold PBS. 411 
Cells were lysed in SDS sample buffer containing ,-mercaptoethanol for 20 minutes at 95°C. 412 
The lysates were resolved by SDS-PAGE and immunoblotted with the appropriate antibodies.  413 
For flow cytometry, MDA-MB-231 or SUM-159-PT cells were stained with an anti-414 
TWEAKR antibody and a secondary phycoerythrin-labelled antibody. As controls, MDA-415 
MB-231 or SUM-159-PT cells were stained only by the secondary phycoerythrin-labelled 416 
antibody, omitting the anti-TWEAKR antibody. Analyses were performed on a FACSCalibur 417 
flow cytometer (Becton Dickinson). 418 
 419 
ELISA for assessing LCN2 and TWEAK 420 
   The ELISA for LCN2 was performed as directed by the manufacturer on 50 -l of cell 421 
supernatants. For TWEAK, cell supernatants were concentrated using the Centricon 422 
(Millipore) prior to performing the ELISA as directed by the manufacturer on 50 l of 423 
concentrated supernatant. 424 
 425 
Invasion assays (chemoinvasion and random invasion assays)  426 
The chemoinvasion assay was performed essentially as described, using Transwell chambers  427 
(Becton Dickinson) with 8--m pore membranes coated with Matrigel (Becton Dickinson). 428 
Cells, co-transfected with the relevant expression plasmids and the pCS2-(n)-,-gal reporter 429 
plasmid, were resupsended after 24 hours in serum-free medium containing 0.1% BSA, and 430 
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 cells were added to each well. Conditioned NIH-3T3 medium was added to the bottom wells 431 
of the chambers. After 6 hours, cells that had not invaded were removed from the upper face 432 
of the filters using cotton swabs, and cells that had invaded to the lower surface of the filters 433 
were fixed for 30 min in 4% paraformaldehyde and then stained with PBS containing 1 mg/ml 434 
 bluo-gal, 2 mM MgCl2, 5 mM potassium ferrocyanide, and 5 mM potassium ferricyanide. 435 
All cells in each Transwell were counted. All the counts were normalised by the efficiency of 436 
transfection. The numbers of cells that invaded in each condition were compared with 437 
the empty vector-transfected condition arbitrary set as a ratio of 1. When the assay was 438 
performed with cells transiently transfected by siRNA, cells were stained with crystal violet 439 
since 95% of the cells were effectively transfected. In some cases, 200 ng/mL recombinant 440 
TWEAK was added for 6 hours to the cells during the assay.  441 
The random invasion assay was performed as reported (Willis et al. 2008).  442 
 443 
Luciferase assay 444 
Cells were cotransfected with the appropriate LCN2 Luciferase reporter construct, 445 
pCS2-(n)-,-galactosidase and NFAT1 expression vector or control vector using 446 
Lipofectamine 2000. After 48 hr, cells were lysed with the Reporter Lysis Buffer (Promega) 447 
and Luciferase and ,-gal activities were measured using the Luciferase Assay System 448 
(Promega) and Galacton-plus (Tropix) on a luminometer. Luciferase activities were 449 
normalized relative to the corresponding ,-gal activities. 450 
 451 
Electrophoretic mobility shift assay  452 
Harvested cells were washed in ice-cold PBS, 0.5 mM DTT, and lysed in buffer with 453 
10 mM HEPES, 10 mM KCl, 15 mM MgCl2. Nuclei were isolated by centrifugation, and 454 
nuclear proteins were extracted in buffer with 20 mM HEPES, 25% glycerol, 420 mM NaCl, 455 
15 mM MgCl2, 0.2 mM EDTA. DTT (0.5 mM) and PMSF (0.2 mM). Binding of nuclear 456 
extracts to 5’-end-IRDye700-labeled probes (Eurofins MWG Operon) was carried out by 457 
incubating the extracts with 50 fmol of labelled probes in 20 _L at room temperature for 20 458 
min in binding buffer (10 mM Tris-HCl (pH 7.5), 50 mM KCl, 3 mM DTT, 0.25% Tween20 459 
and 50 ng/_L poly(dI-dC)). Unbound probes were separated from DNA-protein complexes in 460 
a 5% polyacrylamide gel, and detected after migration on an infrared imaging system 461 
ODYSSEY (Li-Cor Biosciences). Super-shift was obtained by incubating nuclear extracts 462 
with 0.5 _g antibodies (anti-NFAT1 or IgG control) at room temperature for 20 min before 463 
adding the labelled probes. Probe sequences are reported in Supplemental Table 2. 464 
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 465 
ChIP assay 466 
Crosslinking, 48 hr after siRNA transfection, was performed by incubating cells in 1% 467 
formaldehyde for 5 min, and stopped by adding 1:7 volume of 1 M glycine for 5 min. After 468 
washing, cells were scraped with 1 mL cold PBS. After cell lysis, nuclei were isolated in a 469 
first buffer (20 mM HEPES, 10 mM EDTA, 0.5 mM EGTA, 0.25% TritonX100) and then a 470 
second (50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 0.5 mM EGTA), each for 10 min at 471 
4°C followed by centrifugation. Nuclei pellets were suspended in buffer with 20 mM HEPES, 472 
1 mM EDTA, 0.5 mM EGTA, protease inhibitors, and 0.05% SDS. Nuclei were sonicated for 473 
15 min in a Bioruptor (Diagenode). Efficient sonication was verified on Agarose gel. Protein 474 
A/G beads were blocked overnight at 4°C in incubation buffer (10 mM Tris pH 8.0, 150 mM 475 
NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.15% SDS, 1% TritonX100, 0.1% BSA and protease 476 
inhibitors). For each condition, the same amount of sonicated chromatin was incubated 477 
overnight at 4°C with 4 _g anti-NFAT1 antibody or control IgG and 20 _L of 50% 478 
suspension blocked beads in 300 _L final. Afterward, beads were washed twice in buffer (10 479 
mM Tris, 150 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% SDS, 0.1% DOC, 1% 480 
TritonX100), once in the same buffer but with 500 mM NaCl, twice in a third buffer (10 mM 481 
Tris, 1 mM EDTA, 0.5 mM EGTA, 0.25 M LiCl, 0.5% DOC, 0.5% NP-40), and last with the 482 
final buffer (10 mM Tris, 1 mM EDTA, 0.5 mM EGTA). Chromatin was eluted in 400 _L 483 
elution buffer (1% SDS, 0.1 M NaHCO3), and incubated for 30 min at room temperature. 484 
Immunoprecipitated chromatin was reverse-crosslinked with 200 mM NaCl overnight at 485 
65°C, and purified by phenol/chloroform extraction and ethanol precipitation. The pellet was 486 
resuspended in 30 _L water. RT-QPCR was performed as described. The relative proportions 487 
of coimmunoprecipitated gene fragments were determined based on the threshold cycle (Ct) 488 
for each PCR product. Data sets were normalized according to 2 Ct(unspec. Ab = Ig) ) Ct(spec. ab = anti-489 
NFAT1). The fold difference over background obtained for gene regions was further normalized 490 
relative to the value obtained with a primer pair amplifying an intergenic region on 491 
chromosome 10. Each sample was quantified in duplicate and from %3 independent ChIPs. 492 
SEM was determined for each fold difference above the IgG control and intergenic control 493 
region. Primer sequences are reported in Supplemental Table 2. 494 
 495 
 496 
 497 
 498 
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Array hybridization, data analysis and clustering 499 
RNA was purified on Qiagen columns, and its integrity was verified using a Bioanalyzer. 500 
Total RNA was processed following Roche Nimblegen’s instructions to produce double-501 
strand DNA and was sent to Roche Nimblegen. Labelling, hybridization, data collection, and 502 
normalization were carried out according to NimbleGen protocols. The array used was the 503 
human 2006-08-03_HG18_60mer_expression array. Normalised data were then filtered 504 
according to their expression level: for a given comparison, average expression of at least one 505 
of the two compared experimental conditions had to be % 100. For genes targeted by several 506 
Nimblegen’s probes, the average of probe-normalised intensities was calculated to estimate a 507 
single gene signal intensity. We then performed paired Student’s t-tests to compare gene 508 
expression intensities. Genes were considered significantly differentially regulated when fold-509 
change was % 1.5 and p-value $ 0.05. The distance from the gene signal in a given sample to 510 
the corresponding average in the 6 samples (MDA-MB-231 cells transfected with si ctrl or si 511 
LCN2) was calculated for each LCN2-regulated gene. Corresponding values were displayed 512 
and clusterised with MeV4.6.2 from The Institute of Genome Research using Euclidean 513 
distance and complete linkage clustering. Full array data are shown in Supplemental Table 1. 514 
 515 
 516 
Supplementary online data 517 
Supplementary data are available at Journal of Cell Science online. 518 
 519 
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Figure Legends 533 
 534 
Figure 1. NFAT1 up-regulates LCN2 expression to increase the invasive capacity of breast 535 
cancer cells. (A) MDA-MB-231 cells were transiently transfected with control (si ctrl) or 536 
NFAT1-specific (si NFAT1) siRNAs and assayed by RT-QPCR to quantify LCN2 and !-2 537 
microglobulin mRNAs as arbitrary units relative to si ctrl-transfected cells. Immunoblots with 538 
anti-NFAT1 or anti-actin antibodies are shown. (B) Cells were transfected as in (A). Left 539 
panel: Immunoblots with anti-NFAT1, anti-LCN2 or anti-actin antibodies of total cell lysates. 540 
Middle panel: LCN2 protein amount was assessed by ELISA in 50 l conditioned 48-hr-541 
culture medium from the cells. Right panel: Cells were transiently co-transfected with a GFP-542 
expressing vector and either a control (vector) or a T7 epitope-tagged NFAT1 (NFAT1) 543 
vector. After 24 hr, cell lysates of bulk unsorted cells were immunoblotted to probe for 544 
NFAT1 (anti-T7) and actin (anti-actin) to avoid a too strong signal, while endogenous LCN2 545 
(anti-LCN2) and actin (anti-actin) were assessed in lysates of their GFP+ FACS-sorted 546 
counterparts. (C) Cells were transiently transfected with a control (vector) or a HA epitope-547 
tagged LCN2 (LCN2) vector in combination with a ,)gal-expressing vector, and tested after 548 
24 hr for the ability to invade using the chemoinvasion assay. Immunoblots with anti-HA 549 
or anti-actin antibodies are shown. (D) Cells were transiently co-transfected with a T7 550 
epitope-tagged NFAT1 (NFAT1) or control (vector) vector and either control (si ctrl) or 551 
LCN2-specific (si LCN2) siRNAs in combination with a ,)gal-expressing vector, and tested 552 
after 48 hr in the chemoinvasion assay. Immunoblots with anti-T7 (NFAT1), anti-LCN2 553 
or anti-actin antibodies are shown. Statistical analyses were performed relative to si ctrl/ 554 
vector-transfected cells. All data are representative of three independent experiments. Bars: 555 
SE. ", P < 0.05. 556 
 557 
Figure 2. NFAT1 binds to LCN2 promoter region and up-regulates LCN2 expression. (A) 558 
Schematic representation of the LCN2 promoter. Six potential NFAT-binding sites have been 559 
found using the TESS software: http://www.cbil.upenn.edu/cgi-bin/tess/tess; positions relative 560 
to the +1 initiation site are indicated. (B) MDA-MB-231 cells were cotransfected with the 561 
pCS4-(n)-!-gal and the LCN2 promoter plasmids, and with the  NFAT1 (NFAT1) or control 562 
(vector) vectors. After 48 hr, cells were analysed for Luciferase and !-gal activities. 563 
Quantification of LCN2 promoter-mediated Luciferase activity was normalized relative to 564 
that of !-gal. Immunoblots with anti-T7 (NFAT1) and anti-actin antibodies are shown. (C) 565 
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Recruitment of endogenous NFAT1 on LCN2 promoter region was quantified by QPCR after 566 
ChIP using an anti-NFAT1 antibody and comparing si NFAT1- and si ctrl-treated cells using 567 
primers encompassing the -881 or -522 or -501, -441, -409 and -142 potential NFAT1-568 
binding sites. Immunoblots with anti-NFAT1 or anti-actin antibodies are shown. (D) MDA-569 
MB-231 cells were cotransfected with the pCS4-(n)-!-gal and wild-type or mutated (x) LCN2 570 
promoter (pLCN2) plasmids, and cotransfected with the NFAT1 (+) or control (-) vector. 571 
Cells were analysed 48 hr later for Luciferase and !-gal activities. Quantification of LCN2 572 
promoter Luciferase activity was normalized relative to that of !-gal. Immunoblots with anti-573 
T7 (NFAT1) or anti-actin antibodies are shown. (E) Nuclear extracts from MDA-MB-231 574 
cells were incubated with IRDye700-labeled probes containing the wild-type or mutated (*) -575 
142, -409, -501 predicted NFAT-binding sites. The NFAT1/probe complexes were separated 576 
on a 5% polyacrylamide gel. A specific anti-NFAT1 antibody or control IgG were pre-577 
incubated with nuclear extracts before incubation with the IRDye700-labeled probes. Arrows 578 
indicate positions of the super-shifted NFAT antibody–probe complex and asterix position of 579 
the non-specific bands. All data are representative of three independent experiments. Bars: 580 
SE. ", P  < 0.05. 581 
 582 
Figure 3. The NFAT1/LCN2 axis modulates TWEAKR expression. (A) The distance from 583 
the gene signal in a given sample to the corresponding average in the 6 samples (MDA-MB-584 
231 cells transfected with si ctrl or si LCN2) was calculated for each LCN2-regulated gene. 585 
Corresponding values were displayed and clusterised with MeV4.6.2 from The Institute of 586 
Genome Research using Euclidean distance and complete linkage clustering. (B) MDA-MB-587 
231 cells were transiently transfected with control (si ctrl), NFAT1-specific (si NFAT1) or 588 
LCN2-specific (si LCN2) siRNAs, and assayed by RT-QPCR to quantify LCN2 and !-2 589 
microglobulin mRNAs as arbitrary units relative to si ctrl-transfected cells. Immunoblots with 590 
anti-NFAT1, anti-LCN2 or anti-actin antibodies are shown. (C) Cells, transfected as in (B), 591 
were stained after 48 hr with an anti-TWEAKR antibody and analysed by flow cytometry. As 592 
control, cells were stained only with the secondary phycoerythrin-labelled antibody, omitting 593 
the anti-TWEAKR antibody. All data are representative of three independent experiments. 594 
Bars: SE. ", P  < 0.05. 595 
 596 
Figure 4. Reciprocal regulation of the TWEAKR/TWEAK axis and LCN2 expression. (A) 597 
TWEAK and LCN2 (grey line) were assessed by ELISA in 50 l concentrated conditioned 598 
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48-hr culture medium from MDA-MB-231 cells transiently transfected with control (si ctrl), 599 
NFAT1-specific (si NFAT1) or LCN2-specific (si LCN2) siRNAs. Immunoblots with anti-600 
NFAT1, anti-LCN2 or anti-actin antibodies are shown. (B) Both proteins were also assessed 601 
in medium from the cells transiently transfected with increasing amounts of HA epitope-602 
tagged LCN2 (LCN2) and a fixed amount of FLAG epitope-tagged TWEAK (TWEAK), 603 
alone or in combination, or an empty vector control (vector). Immunoblots with anti-HA, 604 
anti-FLAG or anti-actin antibodies are shown. (C) Upper panel: LCN2 was assessed by 605 
ELISA in 50 l conditioned 48-hr culture medium from the cells transiently transfected with 606 
either a control (si ctrl) or TWEAKR-specific (si TWEAKR) siRNAs, and a TWEAK-specific 607 
(si TWEAK) siRNA, alone or in combination. Lower panel: LCN2 expression was evaluated 608 
in cell extracts with an anti-LCN2 or an anti-actin antibody as loading control. (D) LCN2 609 
mRNA quantification in the cells transiently transfected with control (si ctrl) or TWEAKR- 610 
and TWEAK-specific (si TWEAKR/si TWEAK) siRNAs; 36 hr post-transfection (t=0), 611 
vehicle (-) or 2 g/mL actinomycin D (+) were added to the cells. After 8-hr treatment, total 612 
RNA was obtained and RT-QPCR was performed as described earlier to quantify LCN2 and 613 
!-2 microglobulin mRNAs. All data are representative of three independent experiments. 614 
Bars: SE. ", P  < 0.05. 615 
 616 
Figure 5. TWEAKR is an anti-invasive receptor in breast cancer cells. (A) MDA-MB-231 617 
cells were pre-incubated with a TWEAKR-specific neutralizing antibody ( -TWEAKR) or 618 
control IgG (Ig ctrl), and tested in the invasion assay in the presence of TWEAK (+) or 619 
vehicle (-). (B) Cells were transiently transfected with a T7 epitope-tagged NFAT1 (NFAT1) 620 
or control (vector) vector. After 24 hr, cells were pre-incubated with the TWEAKR-specific 621 
neutralizing antibody ( -TWEAKR) or control IgG (Ig ctrl) and tested in the invasion assay 622 
as in (A). Immunoblots with anti-T7 (NFAT1) or anti-actin antibodies are shown. (C) Cells 623 
were transiently transfected with control (si ctrl) or TWEAKR-specific (si TWEAKR) 624 
siRNAs. After 48 hr, cells were tested in the invasion assay as in (A). Cell membrane 625 
TWEAKR expression monitored by flow cytometry is shown in the right panel. (D) Cells 626 
were transiently transfected with control (si ctrl) or LCN2-specific (si LCN2) siRNAs, and 627 
tested in the invasion assay after 48 hr as above. All data are representative of three 628 
independent experiments. Bars: SE. ", P  < 0.05. 629 
 630 
J
o
u
rn
a
l 
o
f 
C
e
ll 
S
c
ie
n
c
e
A
c
c
e
p
te
d
 m
a
n
u
s
c
ri
p
t
 23 
Figure 6. Depending on LCN2 expression TWEAK displays both anti- and pro-invasive 631 
activities in breast cancer cells. (A) MDA-MB-231 cells were transiently transfected with 632 
control (si ctrl) or TWEAKR- (si TWR), TWEAK- (si TW), NFAT1- (si NFAT1) or LCN2-633 
specific (si LCN2) siRNAs, alone or in combination. Cells were tested 48 hr later in the 634 
invasion assay in the presence of TWEAK (+) or vehicle (-). Cell membrane TWEAKR was 635 
monitored by flow cytometry: geometric means of TWEAKR expression intensities are 636 
indicated above the graph. TWEAK amounts in concentrated conditioned media of 637 
transfected cells was monitored by ELISA: values (TWEAK (ng/L) are indicated below the 638 
immunoblots with anti-NFAT1, anti-LCN2 and anti-actin antibodies shown at the bottom of 639 
Fig. 6. (B) The cells were transiently transfected with control (si ctrl), TWEAK- (si TW) or 640 
LCN2-specific (si LCN2) siRNAs, alone or in combination. After 48 hr, cells were tested in 641 
the invasion assay as in (A). Expression of TWEAKR, TWEAK and LCN2 is presented as 642 
described in (A). (C) The cells were transiently transfected with control (si ctrl), TWEAK- (si 643 
TW) or NFAT1-specific (si NFAT1) siRNAs, alone or in combination. After 48 hr, cells were 644 
tested in the invasion assay as in (A). Expression of TWEAKR, TWEAK and NFAT1 is 645 
presented as in (A). All data are representative of three independent experiments. Bars: SE.  , 646 
P < 0.05.  647 
 648 
Figure 7. A working model of the interactions between NFAT1, LCN2, the TWEAKR and 649 
TWEAK. (A) Reciprocal regulatory loops between TWEAK/TWEAKR/LCN2 and NFAT1. 650 
NFAT1 up-regulates LCN2 mRNA and protein expression (1). LCN2 protein regulates 651 
TWEAKR expression (2) and modulates TWEAK protein expression (3). As a retro-control, 652 
TWEAKR and TWEAK inhibit transcription of LCN2 mRNA (4 and 5). (B). In breast cancer 653 
cells there is an equilibrium between inhibitory signalling mediated by TWEAK via the 654 
TWEAKR independently of LCN2 (1) and activating signalling mediated by TWEAK 655 
through binding to an unknown receptor (XR) in cooperation with LCN2 (2). In the absence of 656 
TWEAKR (Without TWEAKR), LCN2-dependent, TWEAK-mediated activating signalling 657 
is promoted and invasion increases (left panel). On the contrary, in the absence of LCN2 658 
(Without LCN2) LCN2-independent inhibitory signalling mediated by TWEAK via 659 
TWEAKR is promoted and invasion is prevented (right panel).  660 
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